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Abstract
We tested the response of CD4' cells and/or total lympho-
cytes from the blood of 22 myasthenic patients and 10 healthy
controls to overlapping synthetic peptides, 20 residues long, to
screen the sequence of the y and 5 subunits of human muscle
acetylcholine receptor (AChR). The oy subunit is part of the
AChR expressed in embryonic muscle and is substituted in the
AChRs of most adult muscles by an e subunit. The 5 subunit is
present in both embryonic and adult AChRs. Adult extrinsic
ocular muscles, which are preferentially and sometimes
uniquely affected by myasthenic symptoms, and thymus, which
has a still obscure but important role in the pathogenesis of
myasthenia gravis, express the embryonic 'y subunit. Anti-
AChR CD4+ responses were more easily detected after CD8+
depletion. All responders recognized epitopes on both the y and
a subunits and had severe symptoms. In four patients the CD4 +
cell response was tested twice, when the symptoms were severe
and during a period of remission. Consistently, the response
was only detectable, or larger, when the patients were severely
affected. (J. Clin. Invest. 1993. 92:1055-1067.) Key words:
embryonic acetylcholine receptor - autoimmunity * T epitopes
Introduction
In myasthenia gravis (MG) ' an autoimmune response against
muscle nicotinic acetylcholine receptor (AChR) occurs ( 1-4).
High affinity IgG antibodies cause AChR destruction/dys-
function and myasthenic symptoms ( 1, 4). Their synthesis re-
quires intervention ofanti-AChR T helper (Th) CD4' cells (5,
6), which have been demonstrated in the blood and thymus of
MG patients, can be propagated in vitro (5-15), and recognize
AChR epitopes in a DR-restricted fashion ( 16).
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Muscle AChRs exist in two developmentally regulated iso-
forms, both formed by four homologous subunits (reviewed in
references 17 and 18). Embryonic AChR is formed by a, #, 'y,
and S subunits. On innervation, the 'y subunit is normally sub-
stituted by a homologous E subunit to yield adult AChR, an
afleb oligomer ( 17-20). The AChR a subunit contains the so-
called main immunogenic region (MIR), i.e., the set oflargely
overlapping epitopes that dominates the antibody response in
MG (21-23), and important constituent elements of binding
sites for cholinergic ligands (reviewed in reference 24). Most
studies on the sequence regions forming T cell epitopes have
focused on the a subunit (10-14). However, since T and B
cells tend to recognize different parts of the same protein anti-
gen ("complementarity" of the T and B repertoire [25, 26]),
other AChR subunits may form epitopes important for sensiti-
zation of pathogenetic T cells. Furthermore, MG patients fre-
quently have antibodies specific for the embryonic AChR (27,
28), and in some cases all anti-AChR antibodies uniquely rec-
ognize embryonic AChR (29). Such antibodies must recognize
epitopes formed primarily or exclusively by the y subunit. Th
cell lines specific for the embryonic AChR, and recognizing
epitopes on the y subunit, can be propagated from MG pa-
tients (30, 31 ).
Particular interest in the anti-AChR sensitization against
the embryonic y subunit is justified by the recent finding that
extrinsic eye muscles (EOM) of adult mammals express the
AChR y subunit (32). This well explains the embryonic-like
electrophysiological properties ofsome EOM AChRs (33, 34).
The EOM are generally the first and sometimes the only mus-
cles to manifest myasthenic weakness, suggesting that the
AChRs they express have unique structural features (33, 34).
The embryonic -y subunit is a likely candidate as the EOM-spe-
cific structure recognized in MG. The y subunit is expressed in
normal thymus (35), further supporting the involvement ofan
embryonic AChR in MG pathogenesis, since the anti-AChR
sensitization might originate within the thymus (36), which in
MG patients is frequently hypertrophic or contains a thymoma
(37), and contains anti-AChR T and B cells (10, 38-40).
AChR-specific long-term Th cell lines can be propagated
from the blood of MG patients by stimulation with pools of
synthetic peptides corresponding to the sequences of the hu-
man AChR a, f3, -y, and 5 subunits ( 13-15, 30, and Moiola, L.,
and B. M. Conti-Tronconi, unpublished observations). How-
ever, long-term Th lines are not ideal to study the Th epitope
repertoire in MG, since during their propagation in vitro selec-
tive clonal loss or enrichment may occur, resulting in a biased
repertoire of the anti-AChR Th lines. Long-term Th lines spe-
cific for the AChR a subunit recognize only epitopes within
four immunodominant sequence regions (14), while direct
testing of unselected CD4+ cells from MG patients' blood re-
veals several other epitopes (41 ). Furthermore, propagation of
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Th lines is time consuming and labor intensive, and very few
patients can be studied by this approach ( 14, 15, 30).
In this study we analyzed the response ofunselected periph-
eral blood lymphocytes and/or of CD8+-depleted, CD4+-
enriched blood cells to overlapping synthetic peptides to screen
the sequences of the human AChR y and 6 subunits. The MG
patients used are the same ones in which we investigated the Th
epitope repertoire on the human AChR a subunit (41 ). The
combined results ofthose two studies should yield a reasonably
comprehensive assessment of the epitope repertoire in MG,
and the frequency among MG patients of a Th response to
embryonic AChR.
Methods
Patients. Table I summarizes the salient clinical features ofthe 22 MG
patients, whose Th repertoire on the AChR a subunit we characterized
previously (41). For 14 patients, CD8+-depleted, CD4+-enriched T
cells were isolated and used to study their in vitro response to peptide
sequences (patients 3, 6-10, 12-16, 18, 19, and 21). For six of these
patients (3, 6, 7, 9, 15, and 19) a similar experiment was repeated using
total PBMC. In eight patients ( 1, 2, 4, 5, 11, 17, 20, and 22) we studied
only the response of the PBMC population. Similar experiments were
carried out with cells from healthy controls (four males, six females) of
different HLA haplotype, 26-44 yr of age.
Peptide synthesis and characterization. We used overlapping syn-
thetic peptides, 11-20 residues long, corresponding to the complete
sequences ofhuman muscle AChR -y (42), 6 (43), and a subunits (44)
which we synthesized, characterized, and described previously ( 12-15,
30, 41 ). The peptides overlapped each other by four to eight residues.
They are indicated by codes that include the letter H for human, the
symbol of the corresponding subunit, and two numbers indicating the
position on the subunit sequence ofthe amino-terminal and carboxyl-
terminal residues of the peptide. The Hy or HA peptides correspond to
the sequence segments ofthe human AChR -y and 6 subunits indicated
along the abscissa of Fig. 2.
Purification ofTorpedo AChR. Native, membrane-bound Torpedo
AChR (TAChR) was prepared from Torpedo californica electric tissue
and characterized as described in reference 12. The specific activity of
TAChR preparations (expressed as nanomoles ofa-bungarotoxin bind-
ing sites per milligram of protein) was 4-7 nmol/mg of protein (pure
TAChR: 7.2 nmol/mg).
CD8' T cell depletion. CD8+ T cell depletion of PBMC was done
using mouse anti-CD8 antibody (OKT8; Ortho Diagnostic Systems
Inc., Raritan, NJ) and "paramagnetic" beads coated with goat anti-
mouse Ig antibody (Advanced Magnetics, Inc., Cambridge, MA) ( 12).
The phenotypes ofPBMC and ofCD8+-depleted, CD4+-enriched cells
(referred to as CD4+-enriched cells) were determined in four experi-
ments by FACSO analysis (FACStarO, Becton Dickinson and Com-
pany, Mountain View, CA) (12). PBMC had relative amounts of T
cells and of the different T cell subsets within the normal ranges. The
phenotypes ofthe CD4+-enriched population was as follows (n = 4): T
cells (CD3+), 61.4±15%; activated T cells (CD3+, DR'), 1.8±0.6%;
CD4+ cells, 55.5±14.3%; activated CD4+ cells (CD4+, DR+) 1.6±1%;
CD8+ cells, 0.5±0.1%; activated CD8+ cells (CD8+, DR+), 0.1±0.1%.
Microproliferation assay. We used CD8+-depleted, CD4+-
enriched cells, or PBMC ifthe yield ofPBMC was too low for purifica-
tion of sufficient CD4+-enriched cells. PBMC or CD4+-enriched cells,
diluted to 1 X 106/ml in RPMI 1640 (GIBCO BRL, Gaithersburg,
MD) with 10% heat-inactivated AB human serum, 2 nM L-glutamine,
100 U/ml penicillin, and 50 jig/mI streptomycin (tissue culture me-
dium) were plated in triplicate in 96-round-bottom-well plates (in du-
plicate ifthe amount of cells was low). No further addition ofantigen-
presenting cells was necessary for the CD4+-enriched cells, because the
CD8+ depletion left sufficient macrophages for antigen presentation.
The cells were stimulated with each ofthe following antigens: PHA ( 10
jg/ml; Wellcome London, UK), T cell growth factor (TCGF; Lym-
phocult; Biotest Diagnostics Corp., Denville, NJ; final concentration of
IL-2, 10 U/ml), TAChR (10 jg/ml), the pools of synthetic peptides
corresponding to the complete sequence ofhuman AChR a (a pool), 'y
(y pool), or 6 subunit (6 pool) (0.05, 0.1, 0.5, 1, and 5 jg of each
peptide/ml), and the individual synthetic peptides present in the y and
6 pools ( 10 jg/ml). The pool of synthetic peptides corresponding to
the complete sequence ofhuman AChR a, -y, and 6 subunits were used
to determine the antisubunit response ofMG patients and healthy con-
trols. The individual synthetic peptides were used to determine the
sequence segments containing epitopes recognized by the CD8+-de-
pleted, CD4+-enriched population, the PBMC, or both. Blanks were
wells with cells that did not receive any stimulus, and wells with cells
plus a 19-residue synthetic peptide unrelated to AChR (residues 1-19
of the major intrinsic protein of bovine lens [45], 10 jg/ml); the val-
ues obtained with the two different blanks were consistently compara-
ble. Whenever possible, more than triplicates of the unstimulated
blanks were seeded to better assess the culture-to-culture variability of
[13H]thymidine incorporation of unstimulated cells. After 5 d the cul-
tures were pulsed for 16 h with [3H]thymidine (1 jICi per well; specific
activity, 6.7 Ci/mmol; Amersham Corp., Arlington Heights, IL). Cells
were collected with a Titertek multiple harvester (Skatron, Inc., Ster-
ling, VA) and [3H]thymidine incorporation was measured by liquid
scintillation.
Searchfor sequence similarities between AChR sequence segments
and unrelated proteins. We used the program FASTDB (version 5.4)
(46) ofthe Intelligenetics suite (IG Inc., Mountain View, CA) to search
for sequence similarities between the protein sequences in the data-
bases PIR 29 and Swiss-Prot 19, and segments ofthe AChR a, -y, and 6
subunits found to contain T epitopes (26 and this study: a 19-34, a32-
51, a48-67, alOl-120, al18-137, alSl-168, a191-207, a293-308,
a304-322, a320-337, a387-405, a403-421, a419-437, Iy5-34, y3O-49,
y60-79, y75-94, -y90-109, y105-124, y135-154, y180-202, y2O3-222,
,y218-237, y233-252, y248-267, y263-273, y269-288, y284-303,
'y297-312, y3O6-325, -y321-340, y351-370, 'y366-385, 'y381-400,
,y411-430, y476-495, 61-20, 661-80, 691-110, 6106-125, 6121-140,
6151-170, 6196-215, 6213-230, 6226-245, 6241-260, 6256-275, 6271-
290, 6346-362, 6363-386, 6373-392, 6446-465, 6461-480, 6476-496),
or control AChR sequence regions that in our studies (this study and
references 15 and 26) were never recognized by CD4+T cells fromMG
patients (a63-80, a76-93, a89-105, a135-154, a203-218, a214-234,
a230-249, yl-20, 'y120-139, yI50-169, 'y165-184, yI90-209, y336-
355, y396-415, -y438-457, y470-489, 631-50, 676-95, 6136-155, 6166-
185, 6301-320, 6331-350, 6401420, 6416435, 6431450).
Results
Response ofPBMC and CD4+ enriched cells to TAChR
and to peptide pools
CD4+-enriched cells from 7 ofthe 14 patients tested responded
to both the y and the 6 pools (Fig. 1). When we used PBMC,
only patients 11 and 20 (out of the 14 patients for which the
response of PBMC was tested, see Methods) responded to the
peptide pools (Fig. 1). Fig. 1 also reports the response of the
same patients to the a pool. Several patients responded to the
three pools to comparable extents ( 10, 12, 14, and 21 ). Other
patients did not recognize one pool (the y pool in patient 7, the
a pool in patient 14, and the 6 pool in patient 20). It is conceiv-
able that, even in the absence of a CD4+ response to epitopes
on a given AChR subunit, the anti-AChR antibodies of that
patient may still recognize epitopes formed by residues within
that subunit: this is particularly likely for the a subunit, whose
corresponding a pool was not recognized by patient 14, since
the a subunit contains the MIR, the set of largely overlapping
epitopes which dominates the antibody response in MG (21-
23). However, given the conformation dependence of most
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Table I. Characteristics ofthe Myasthenic Patients
A. Donors of CD8+-depleted cells
Patient Experiment Age, sex DR* Disease classt Clinical course anti-AChR AbsO Thymectomy l.S.
nM
Responders
3 1 35, F 1, 7 4 Worsening 2.44 Y Y
2 2 Improved after PLEX 0.51 Y
7 27, F w17(3), 4 2 Worsening 0 N Y
10 1 24, F 9, w8 4 Worsening 10.2 N N
2 4 Improvement after PLEX (10.2) N
12 41, F 2, 6 4 Worsening 47 Y Y
13 21, F wlO, w12(5) 4 General weakness 38.4 Y Y
14 1 25, F 5 4 Worsening, some 0.06 Y Y
21 2 27, M w 1l(5) 4 Acute worsening since 0.58 Y Y
Nonresponders
6 87, M 1, 4 2 Static, mild (1.81) N Y
8 77, M 8 4 Worsening 3.27 N N
9 43, F ND 2 Stable, mild weakness (84.4) Y Y
14 2 25, F 5 2 Stable, moderate weakness (0.06) Y Y
15 23, F w13(6), wl1(5) 2 Stable, mild weakness (4.49) Y Y
16 75, M 6 IR Static. minimal weakness (4.73) N Y
18 74, M 2, 7 IR Static, minimal weakness (3.55) N Y
19 46, F w15(2), 4 2 Improvement with I.S. (1.15) Y Y
21 1 27, M w 1l(5) 2 Stable, moderate weakness (0.48) Y Y
B. Donors of PBMC
Patient Experiment Age, sex DR* Disease classt Clinical course anti-AChR Abs (nM)5 Thymectomy I.S.
Responders
11 72, M 4 4 Moderate generalized, 0.8 N Y
20 52, M 2, 7 2 Recent worsening ND Y Y
Nonresponders
1 27, M 3 4 Recent worsening 5.78 Y N
2 74, M ND 2 Recent worsening 1.59 N Y
3 35, F 1, 7 2 Worsening 1.75 Y Y
4 69, M 5, 7 2 Minimal weakness, 1.07 N Y
5 54, M ND 4 Progressive weakness 0.33 N N
6 87, M 1, 4 2 Static, mild (1.81) N Y
7 60, M w17(3), 4 2 Recent worsening 0 N Y
9 43, F ND 2 Progressive fatigue 84.4 Y Y
15 23, F w11(5), w13(6) 2 Stable, mild (4.49) Y Y
17 37, F 3, 4 4 Slow worsening 81.7 N Y
19 46, F wl1(5) 4 Worsening 2.76 Y Y
22 30, F W17(3) 4 Static, moderate 9.46 N Y
General weakness
ND, not determined; QD, daily; PLEX, plasma exchange; I.S., immunosuppressive treatment; I.R., in remission. * Determined by standard
lymphocytotoxicity (1, 3, 4, 6, 8, 11, 12, 14, 16, 17, 18, and 20) as described in reference 78 or by RFLP and oligonucleotide hybridization (7,
10, 13, 15, 19, 21, and 22) as described in reference 79. t Classified as described in reference 80. § The anti-AChR antibody titers, measured
as described in reference 81, were usually evaluated on serum collected the day of the experiment. When in brackets, the titers were determined
within 1 yr from the day of the experiment.
anti-AChR antibodies in MG (1), in general synthetic AChR
sequences cannot be used to detect binding of antibodies
against native AChR, and therefore we could not address this
issue using the synthetic peptide approach.
Four patients (Table II) were tested twice, when their clini-
cal condition was deteriorating and when it was improving (3,
10, 14), or when the clinical situation had not yet deteriorated
(21 ). Patients 3, 14, and 21 responded to the peptide pools
only when they were severely affected. Patient 10 responded to
all three peptide pools in both experiments.
Most patients that responded to the peptide pools re-
sponded vigorously to TAChR (Fig. 1). Exceptions were pa-
tients 7, 10 (experiment 2), 21, and 1 1. They may recognize
epitopes not conserved in human and Torpedo AChRs.
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The rate of cell proliferation of unstimulated PBMC or
CD4+-enriched cells was relatively low (< 1,600 cpm), with
the exceptions of patients 10, 12, and 13 (Fig. 1 and Tables III
and IV). These patients had the highest level of anti-AChR
antibody ( 10.2, 47, and 38.4 nM, respectively; see Table I).
The high basal rate of proliferation of their lymphocytes may
be due to the presence of activated anti-AChR B cells. Cells
from controls did not respond to TAChR or to peptide pools.
Response ofPBMC and CD4+-enriched cells from MG
patients to individual synthetic sequences ofthe
human 'y and a subunits
The individual peptides forming the y and a pools were used in
microproliferation assays to detect epitope-specific response of
CD4+-enriched cells or PBMC. Cells from controls never re-
sponded to any individual peptides. Tables III and IV report
the peptide sequences recognized by each patient. Boldface,
boxed values indicate statistically significant responses (P
< 0.005 orP < 0.001 as assessed by a t test). The relatively high
scattering of the data may be due to the long times (- 24 h)
that elapsed between blood collection and the experiment, and
to the low frequency of precursors specific for a given AChR
epitope. Experiments assessing the frequency of anti-AChR T
cells in the blood ofMG patients reported an average frequency
of 1:30,000 or less (47, 48). Even assuming that this sequence
can be significantly higher in the severely affected patients that
responded to the AChR epitopes, since each patients recog-
nizes several epitopes on the AChR molecule, the frequency of
T cells specific for a given T epitope is probably low enough to
be a source of inhomogeneous distribution of epitope-specific
CD4+ cells among microcultures containing I05 total cells.
Response ofPBMC. Only one ( 11 ) ofthe 14 patients whose
PBMC were tested clearly recognized individual peptide se-
quences, in agreement with his good response to both the y and
5 pools (Fig. 1 ). Patient 11 recognized eight peptide sequences
from the y subunit and two from the 5 subunit (Tables III and
IV), which were not in homologous regions of the y and 5
subunits. Patient 20, whose PBMC had a marginal response to
the -y pool and none to the 5 pool, did not delectably recognize
any peptide sequence.
Figure 1. Response to different stimuli of
3 ~ CD4+-enriched cells or PBMC from the nine
MG patients that responded to synthetic AChR
antigens, measured by microproliferation as-
2 ~ l say. The incorporation of [3H]thymidine inthe absence of any stimulation, or in the pres-
ence of 5 zg/ml a pool, an optimal stimula-
1 - tory concentration (0.5-5 ug/ml of each pep-
tide) of y and S pools, and purified TAChR
(10 ,g/ml) is reported. The cells always re-
sponded vigorously to PHA (10 Mg/ml) and
O t.#LIP. O I-2 (10 U/ml) (not reported). See text for
experimental details.
Response ofCD4 '-enriched cells. 8 ofthe 14 patients tested
recognized individual synthetic sequences (Tables III and IV).
The PBMC from responder patients 3 and 7 were also tested,
and they did not respond to any individual peptide or peptide
pool.
All CD4+ responders had severe symptoms and they were
mostly young women, while all but one CD4+ nonresponder
were improving or had mild, stable symptoms (Table I). To
verify the correlation between severity of the symptoms and
CD4+ response to AChR sequences, four responders (3, 10, 14,
and 21; see Table II) were tested twice, when they had severe or
worsening symptoms and when they had mild, stable symp-
toms. Patients 14 and 21 recognized AChR sequences only
when they were severely affected (Tables II-IV). The other two
patients recognized several peptide sequences when severely
affected, and only one or two peptides after recovery (Tables
II-IV).
Similarities ofAChR a, 'y, and 5 subunit sequences with
unrelated proteins
Several AChR peptides recognized by CD4+ cells on the a
(41 ), y, and 6 subunits, and several control AChR sequence
segments, had strong similarities with sequence regions of
unrelated proteins ofmicrobial origin. They are summarized in
Table V, where the a, y, and 5 peptides are aligned on the
unrelated, similar sequences. Identical or conservatively substi-
tuted residues are indicated with boxed, boldface characters.
The sequence pairs containing segments of 9-16 residues with
75% or more residues identical or conservatively substituted
are reported. Insertions/deletions introduced to optimize the
alignment were counted as nonconservative substitutions. A
length of 9-16 residues was chosen because of the length of
peptides found to bind MHC molecules: eight or nine residues
for MHC class I presented peptides (49-52), and somewhat
longer sequences forMHC class II presented peptides (53, 54).
Discussion
In this study we identified several 20-residue sequence seg-
ments of the human AChR y and 6 subunits forming epitopes






Table II. The Response ofCD4+ Cells to AChR Epitopes Is Related to the Clinical Status ofthe Patients
Patient Experiment Clinical status Basal* y pool* 6 pool* a pool* y peptides 5 peptides











2 Improving 466±31 1,985+41 1,423±48 432±178 None 691-110
10 1 Worsening 3,237±789 18,204+4,990 10,115+4,795 14,944±2,716 y75-94 6461-480
6476-496
2 Improving 6,240±624 18,484±3,306 14,934±2,409 14,944±2,716 y75-94 691-110








2 Stable 236±24 801±203 463±140 773±76 None None
21 1 Stable 101±32 236±168 141±33 49±18 None None
2 Acute worsening 464±120 13,233±588 3,175±945 6,504±861 -y75-94 691-110
-y381-400 6196-215
6241-260
* The values are averages±SD of the [3H]thymidine incorporation of triplicate microproliferation cultures in the presence of the indicated AChR
synthetic antigens. Basal refers to the [3H]thymidine incorporation of unstimulated microcultures. See text for experimental details.
recognized by autoimmune Th cells of MG patients, and we
demonstrated that sensitization against the embryonic T sub-
unit, which is expressed in the thymus (35) and in EOM (32),
frequently occurs in MG. Although each patient had an individ-
ual pattern of response to the synthetic sequences, some re-
gions of the y and 6 subunits were recognized by several pa-
tients of different DR type, confirming that immunodominant
regions for Th sensitization exist in human AChR ( 14, 31, 41 ).
The peptides used overlapped by approximately five resi-
dues. Although we may have missed epitopes not represented
by our peptides (e.g., split between peptides, or contained in a
peptide that folds into a secondary structure incompatible with
HLA-DR binding, or due to negative effects exerted by flank-
ing residues [ 55, 56 ]), we should still detect a significant part of
the T epitope repertoire.
Whenever possible we used a cell population depleted of
CD8 + cells because these cells inhibit the in vitro response of
autoimmune CD4+ T cells to AChR epitopes ( 12 ). An inhibi-
tory influence of CD8 + cells was confirmed by this study be-
cause the PBMC ofmost patients did not respond to any AChR
antigen, regardless of their clinical conditions. Further, the
CD4+-enriched cells from two patients (3 and 7) responded
well to hy peptides, 6 peptides, or both (Tables III and IV), while
their PBMC did not respond to any AChR peptide (not re-
ported).
All CD4' responder patients had severe symptoms and
many were young women (Table I). A correlation between
CD4' response to AChR epitopes and MG severity was con-
firmed by testing four patients at times of different disease se-
verity; improvement of the symptoms always coincided with
reduction or disappearance of the CD4' reactivity to AChR
peptides (Table II). These findings agree with previous studies
which suggested a correlation between CD4' response to the
AChR a subunit and symptom severity ( 12, 41 ). No correla-
tion existed between lymphocyte response to AChR sequences
and anti-AChR antibody titer, in agreement with previous re-
sults on the CD4' T cell response to AChR a subunit se-
quences ( 12, 41 ). The responders included two patients with
high antibody titer ( 12 and 13, with 47 and 48 nmol, respec-
tively), but the patients with the highest titers of antibody to
the AChR (9 and 17) did not respond to y and 6 subunit epi-
topes at the T cell level. Several patients with little or no detect-
able anti-AChR antibody (7, 14, 3 [experiment 2], 21 [experi-
ment 2], and 11 ) had detectable T cell responses. Since there is
a poor correlation between antibody titer and disease severity,
and the total anti-AChR antibody titer does not give clues to
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Table V. Similarities with Microbial Proteins ofHuman AChR Sequence Regions Forming TEpitopes, and of Control AChR Sequences
T epitopes
a19-34----------- VR PDHR QVVVT V G
FRPJSRQVVEVGAM.-----------.
V R P E D|H|R Q V VTEVTV G
ER P 13I|| B V V|EM C - - - - - - - - - - -
VRPEMDIHQVVEVDTVG
FRPDDSRQVLBIGAM-----------
a48-67----------- Q I |V TTQ N ]R L | Q Q W V D N L K W
G S|V TSL8Q S|RD N WVD YL Y AC ---- --
a151-168-------- Y D G S|V V A I N -- P B S|D Q P ]L S
LDGL|V VAA PBSRTT LEF ------
a293-308-------- V I N T H H R S P S T H V
SS SS HH RS PS P RK ---_-__-__-_--_--_-
V15-34----------- Y D|P N L R|P A E|R D S D V V NLV
T PADLRTF SRDTDVVNHLL ------
y30-49---------- NL K L T L T I N B R E
|N V DKLGLK KAEIQL NEBR EIK - -- ---
N V S L K L T L T N L I S L N E RE E A
I VS LL TF LN VL I T LNN RY KH -- --- -
y6O-79--- W PRD YBGLWWVLR
|RVR|TAT|RD YA G LYV L Rl----------
y180-202 ------- NG W A IQHP R NML L D|PAP
LNDEDCAHWKEAKMLL DINTP _
y218-237-------- R P L|F|Y V I N I|A P C
R P I|D|Y V I N I E V D ------ ---- --- -
y336-355-------- E - CLS E L L F Q|Q|W Q R Q|G
RVAVNH|LPR-LIFQVWQRSW -----
Regulatory protein GyiR. Streptomyces griseus
(JQ0490*)
Early E2A DNA-binding protein. Human adenovirus
(DNB24ADE41t)
DNA ligase. E. coli (LEQCC6*)
Glycerol operon regulatory protein. Streptomyces
coelicolor (GYLR$STRCO*)
Sigma lbNS protein. Reovirus type 2 (D34829*)
Alpha-dextrin endo-1,6-glucosidase. Klebsiella
pneumoniae (A32880*)
Hypothetical protein 1. Duck hepatitis B virus (S 12843*)
Hypothetical protein UL71. Human cytomegalovirus
(UL71$HCMVAt)
RNA polymerase sigma-E factor precursor. Bacillus
subtilis (RPSE$BACSUt)
Early E3 22.2-kD protein. Canine adenovirus type I
(E322$ADECIt)
US7 protein. Herpes simplex virus type 2 (QQBE88*)
Genome polyprotein (capsid C protein). Dengue virus
type 2 (POLG$DEN2P*)
Adenylate kinase. Bacillus subtilis (SK684*)
VPX protein. HIV type 2 (110). (VPX$HIV2Dt)
H V R - - -P L A P A A V QDTQ S R|L Q]G
S AQSRIWE M-
H V R P L A P A A V]T Q[ - - - Q N G
PQMG.AAGAS JYS SRMNWLSAG-S --
HVRPLAAAV DTQSRLQH
FVS3LLK-W[|L A PT - ----
Cytochrome c oxidase, chain Va precursor. Yeast
(OTBy5A*)
L4 PVHI proteins. Human adenovirus 41 (S10214*)
Polyprotein hepatitis C virus (PS0104*)
,y381 400 ------- W HRQGL V A IA A LE L EIK G P ELL
K Q RL S A Q I A L E K L S A R R G N - - - - - - Raffinose invertase. E. coli (RAFD$ECOLP)
W Q R Q G LQV A A A L E K L SEKaGP ELA
S G F R E QIV A A|W|L E R L S A|8 A 9 Ll- - - - - - Ipa protein. Shigellaflexneri(A35149*)
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y366-385-------
Table V. (Continued)
891-110---------- E[I V L|E N|N N DG[S[F Q I S|Y S C N V
I |I V LH P|N N D G I |H R L DG L K H M
6241-260-------- F|M V N L V F Y L P A D G E K T VA
CMVNLGFSLPAFGKTAQGT -
6346-362-------- D]P S P G A L V R R SI L GY
FWE[SP G A L L |F LN T L G|T - - - - - - - - -
D G P S P G A L V R R S S S L G Y
DGAAALAMIS SSSLGG ---------
6373-392-------- K S S D LF [E R Q S E|R H G [ A R R
EL.LG E R Q S EIQ L KLD N E
Control sequences
a83-80----------- Y[N L [W]NPD[ Y[G G R R I|H I
E|S L R W VP GNL S P R R I|A Y - - - - - - - - -
a89-105---------- [D L V L Y N [A- G -FAI -K
ID L V L Y Nl-GYD-MIFS G - -- -- ---
y120-139 -------- P P |A I F R S A |C I S V T Y F P F D W
LNAIFRAAHSKGGAGT FGF ------
y165-184-------- T I W I F I |D P E A F T EN G E W
OMSDJVVNFDPAAFTENVFH ------
y190-209 -------- P K M L L D P AA P A Q E - - H Q K V
AJQ A G P E P A A P A Q E D DAJL M P T - - - -
831-50----------- [D V ALALT L S N L I S1L K E V E E
LIGAVLAJNTLSNLI SAI LL I------
6136-155 -------- Y F P F DWQNC S |L F S S LXYA
L SYLLWS[VLLRFSSTiTT -----.
6331-350-------- L E -|T L P E L1LH S R P A E D P P
YDK T L P F L KIP D V Y TLSJQ - -
|L T L P ELP - - - H RSP AE- RG P P
|L E $ L P E LP S TLTILRI - EG NR LV - -
E3a 10.5-kD protein. Human adenovirus 5.
(E31 1$ADE05t)
traU protein precursor. E. coli (TRAU$ECOLIt)
ilvA leader peptide. E. coli (E26570*)
Hypothetical protein, 12.4k. Human adenovirus 41
(S10213)
FPr protein. Salmonella typhimurium (JE0023*)
Arginase. Yeast (AGRI$YEASTI)
N-Acetylneuraminate lyase. E. coli (NPL$ECOLIP)
Chemotaxis cheA protein. S. typhimurium (A28959*)
a-Agglutinin precursor. Yeast (AGA1$YEASTt)
Tropomyosin-like protein. Yeast (TPM$HANPOt)
Hypothetical protein 5. E. coli (YTI5$ECOLI*)
Sialidase. Influenza B virus (NMIV4t)
Reverse transcriptase. Human foam virus
(POL$FOAMVt)
60-kD antigen. S.flexneri (B35149*)
For 44 sequence regions of the human AChR a, y and 6 subunits identified in this or in previous studies (14, 15, 31) as forming epitopes for CD4+
cells, and for 26 control AChR sequence segments corresponding to synthetic peptides never recognized by CD4+ cells from MG patients, we
searched for similarities with the sequence of the proteins present in the data bases PIR 29 and Swiss-Prot 19. The table reports only the sequence
regions for which similarities with unrelated microbial proteins were found. See text for further details.
* From PIR 29.
* From Swiss-Prot 19.
the involvement of the different AChR subunits in the anti-
AChR antibody response, it is impossible to reach any conclu-
sions on the complex relationships between the extent ofT cell
sensitization, antibody synthesis by the AChR specific B cells,
and severity of the symptoms. The finding that the two anti-
body-negative patients (7 and 14) had T cell sensitization to
the AChR suggests that at least in some cases ofantibody-nega-
tive MG an immune anti-AChR response occurs.
Table VI summarizes the response ofCD4 + -enriched cells
and PBMC from MG patients to the y and 6 peptides, and to
similar peptides corresponding to the a subunit sequence (41 ).
Although all responders recognized one or more epitopes on all
three AChR subunits, including the embryonic y subunit, the
relative contribution of each subunit to the repertoire of anti-
AChR Th cells was characteristic for each patient. Therefore,
several AChR epitopes are involved in Th sensitization in any
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Table VI. Response ofCD4+-enriched Cells and PBMC to Synthetic Human AChR Sequences
Patient (experiment No.) a pool Y pool 5 pool a peptides* y peptides 5 peptides
3 (1) ++ ++ +++ +++++ ++++ +++++++++++
3 (2) - - - + - +
7 +++- + + +++ +
10 (1) ++ ++ + +++ + ++
10 (2) + + + + + +
11t ++ + + ++
12 ++ ++ ++ ++++++ ++++++++++ +++++++++
13 + + + ++ ++
14 ++ ++ +
21(2) + + + + ++ +++
Notice that while for responses to the peptide pools the number of pluses indicates the extent of the response, for responses to the indi-
vidual synthetic peptides (columns labeled a peptides, y peptides, and a peptides) the number of pluses refers to the number of pep-
tides recognized within each AChR subunit by the patients. 5PBMC were used; otherwise CD4+-enriched cells were used. * The results for
the a pool and the a peptides are from reference 41.
MG patient, and Th sensitization against the embryonic y sub-
unit occurs frequently in MG, in agreement with easy propaga-
tion ofCD4+ cell lines specific for embryonic AChR (30, 31 ).
Recognition of y subunit sequences is not due to cross-reactiv-
ity with homologous regions ofother subunits, because compar-
ison of the sequence segments recognized by the same patient
on the y and a subunits (Tables III and IV) clearly indicates
that different subunit regions form epitopes for the same pa-
tient. Comparison of the - with the a subunit is particularly
meaningful, because their similarity is much higher than with a
and fB subunits ( 19, 20).
Even if the anti-AChR sensitization involves an embry-
onic-like AChR within the thymus, Th cells directed against
the a, fS, and a subunits, shared by embryonic and adult
AChRs, will be preferentially stimulated and expanded by the
relatively abundant muscle AChR. Anti-y subunit Th cells
may eventually become a small minority. Still, their existence
in many MG patients points to an origin of the anti-AChR
response in a tissue other than skeletal muscle, and possibly
within the thymus. The beneficial effects of thymectomy on
MG symptoms (36, 37) may be due to removal ofa reservoir of
embryonic AChR in a tissue rich in antigen-presenting cells.
The relatively large number of epitopes recognized by any
patient indicates that at least during the later phases of the
anti-AChR response, when myasthenic symptoms become ob-
vious, the whole AChR molecule is involved in the autoim-
mune response, but it does not exclude that the anti-AChR
sensitization may be initiated by an altered form ofthe AChR,
as occurs in experimental systems (57), or by mechanisms of
molecular mimicry between a small region on the AChR mole-
cule and a viral or bacterial epitope: once tolerance to a multi-
determinant antigen is broken for one epitope as result ofmo-
lecular mimicry or altered selfproteins, responsiveness to mul-
tiple epitopes may develop (58). We therefore searched for
sequence similarities between sequence segments ofthe AChR
forming T epitopes and unrelated proteins. We did similar
searches for control AChR sequences, i.e., sequence regions of
the a, y, and 6 subunits never recognized by the MG patients
we studied (14, 15, 31, 41). We cannot exclude that some of
these control sequences may form T epitopes for other MG
patients. Although several T epitope and control sequences re-
sembled sequence regions of other proteins, including proteins
ofcommon human pathogens (Table V), our findings do not
allow conclusions about the role of molecular mimicry in au-
toimmune responses, because similarities with microbial pro-
teins were not uniquely found for T epitopes, and even small
sequence differences may drastically modify or abrogate the T
cell recognition ofan epitope sequence (59, 60). Potential im-
mune cross-reactivity between unrelated microbial and mam-
malian proteins may be relatively frequent because certain
short amino acid sequences (three to five residues), perhaps
corresponding to specific three-dimensional motifs, occur with
higher frequency than statistically expected, making it likely
that fragments of alien proteins long enough for T epitope for-
mation (49-54) may share substantial similarities with self
protein fragments (61, 62). A complete purging from the T
repertoire of all potentially autoreactive T cells would severely
limit the T repertoire and impair the ability to respond against
pathogens. Further filters must exist in the immune system to
avoid widespread occurrence ofautoimmune phenomena: for
example, the necessity for an alien sequence, resembling a self
protein, to be processed and presented, and the availability of
potentially autoreactive T clones.
Three control sequences (-y165-184, -y190-209, and 631-
50) share virtually identical stretches ofseven to eight residues
with microbial proteins from common human pathogens/
guests (yeast, Escherichia coli, influenza virus). It is conceiv-
able that the use of biosynthetic or synthetic AChR sequences
inclusive of these regions may propagate corresponding T
clones from healthy controls and give the misleading impres-
sion of a high frequency of anti-AChR Th cells in healthy hu-
mans.
The data in Fig. 2 summarize the location on the y and 5
subunit sequences of the peptide epitopes identified in this
study (hatched columns) and those identified previously (15,
31) by the use of anti-AChR T cell lines (black columns).
Many epitopes are present on both the oy and the a subunits. On
the y subunit, two sequence regions are recognized by several
patients (the overlapping peptides y6O-79/-y75-94 and y321-
340). Also along the 5 subunit, four relatively immunodomi-
nant sequence regions seem to exist (691-110,6196-215/6213-
230, 6256-275/6271-290, and 6461-480/6476-496), recog-
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Figure 2. Frequency of recognition of peptide se-
quences on the y subunit (A) and on the 6 subunit
(B) by the eight responder MG patients of this study
(hatched columns) and by anti-AChR T cell lines
propagated from different MG patients and specific
for the 'y and 6 subunits (black columns). At the bot-
tom ofeach panel, a schematic representation of the
location of the sequence regions forming T epitopes
on the y and 6 subunit sequences is given. The epi-
topes forming sequence regions are indicated as gray
segments, while white segments indicate immuno-
dominant peptides recognized by patients of different
class II haplotype. The four putative transmembrane
regions (Ml-M4) are indicated in black. The se-
quence segment aminoterminal to the Ml region
(residues 1 to - 220) is believed to form an extracel-
lular domain, and the segment between M3 and M4
a cytoplasmic domain. The transmembrane topology
ofthe carboxyl terminal sequence segment following
M4 is still under debate but is probably extracellular
(reviewed in references 19 and 20; see also reference
82).
nized by patients of different DR haplotype. Because these
immunodominant sequences are 20 or more residues long,
they may contain nested epitopes, recognized in association
with different DR molecules (63-66). Recognition ofthe same
sequence by patients of different DR haplotype may be due to
the promiscuous binding of peptides to the human DR mole-
cules (67). The large number ofCD4' epitopes recognized by
MG patients on the AChR molecule makes it unlikely that
epitope-specific immunosuppressive therapies will be easily
and expeditiously developed for MG.
The anti-AChR antibody response in MG is also polyclonal
(1-4), and even antibodies directed to the same AChR epitope
have different idiotypes (68, 69). However, it is likely that only
antibodies against particular AChR epitopes, which should in-
clude the MIR (70, 71 ), cause AChR destruction and myas-
thenic symptoms, as suggested by the lack of correlation be-
tween the antibody titer and the severity ofMG ( 1-4, 72, 73)
and by experiments that tested the ability -f different anti-
AChR (74). It is possible that among the many anti-AChR Th
clones present in MG patients, only those directed against par-
ticular epitopes are involved in the development ofMG symp-
toms, due to the preferential pairing with B cells secreting anti-
bodies ofhigh pathogenetic potential. Further investigations in
mice with genetically determined severe combined immunode-
ficiency (75-77), xenografted with different combinations of
PBMC from MG patients and AChR CD4' cells ofthe defined
epitope specificity, may resolve this issue.
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